These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 36852510)

  • 1. L1-CAM in Mucinous Ovarian Carcinomas and Borderline Tumors: Impact on Tumor Recurrence and Potential Role in Tumor Progression.
    Wiedenhoefer R; Schmoeckel E; Grube M; Sulyok M; Pasternak I; Beschorner C; Greif K; Brucker S; Mayr D; Kommoss S; Fend F; Staebler A; Fischer AK
    Am J Surg Pathol; 2023 May; 47(5):558-567. PubMed ID: 36852510
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A case report of mucinous borderline ovarian tumor with recurrence as invasive carcinoma with high copy number alterations.
    Wakazono E; Taki M; Watanabe K; Yamanoi K; Murakami R; Kakiuchi N; Yamaguchi K; Hamanishi J; Minamiguchi S; Ogawa S; Mandai M
    Int Cancer Conf J; 2024 Oct; 13(4):520-524. PubMed ID: 39398914
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The frequency and prognostic role of P53 and P16 immunoexpression in primary ovarian mucinous tumors.
    Nergiz D; Yıldırım HT; Süren D; Sadullahoğlu C; Yıldırım Ş; Üreyen I
    Ann Diagn Pathol; 2024 Oct; 72():152330. PubMed ID: 38772285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histological classification of mucinous ovarian tumors: inter-observer reproducibility, clinical relevance, and role of genetic biomarkers.
    Genestie C; Auguste A; Al Battal M; Scoazec JY; Gouy S; Lacroix L; Morice P; Pautier P; Leary A; Devouassoux-Shisheboran M
    Virchows Arch; 2021 May; 478(5):885-891. PubMed ID: 33009577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. L1 (CAM) (CD171) in ovarian serous neoplasms.
    Daponte A; Kostopoulou E; Kollia P; Papamichali R; Vanakara P; Hadjichristodoulou C; Nakou M; Samara S; Koukoulis G; Messinis IE
    Eur J Gynaecol Oncol; 2008; 29(1):26-30. PubMed ID: 18386459
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses.
    Kang EY; Cheasley D; LePage C; Wakefield MJ; da Cunha Torres M; Rowley S; Salazar C; Xing Z; Allan P; Bowtell DDL; Mes-Masson AM; Provencher DM; Rahimi K; Kelemen LE; Fasching PA; Doherty JA; Goodman MT; Goode EL; Deen S; Pharoah PDP; Brenton JD; Sieh W; Mateoiu C; Sundfeldt K; Cook LS; Le ND; Anglesio MS; Gilks CB; Huntsman DG; Kennedy CJ; Traficante N; ; DeFazio A; Kaufmann S; Churchman M; Gourley C; Stephens AN; Meagher NS; Ramus SJ; Antill YC; Campbell I; Scott CL; Köbel M; Gorringe KL;
    Mod Pathol; 2021 Jan; 34(1):194-206. PubMed ID: 32724153
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is it necessary to perform routine appendectomy for mucinous ovarian neoplasms? A retrospective study and meta-analysis.
    Cheng A; Li M; Kanis MJ; Xu Y; Zhang Q; Cui B; Jiang J; Zhang Y; Yang X; Kong B
    Gynecol Oncol; 2017 Jan; 144(1):215-222. PubMed ID: 27889016
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted deep sequencing of mucinous ovarian tumors reveals multiple overlapping RAS-pathway activating mutations in borderline and cancerous neoplasms.
    Mackenzie R; Kommoss S; Winterhoff BJ; Kipp BR; Garcia JJ; Voss J; Halling K; Karnezis A; Senz J; Yang W; Prigge ES; Reuschenbach M; Doeberitz MV; Gilks BC; Huntsman DG; Bakkum-Gamez J; McAlpine JN; Anglesio MS
    BMC Cancer; 2015 May; 15():415. PubMed ID: 25986173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mucinous borderline ovarian tumors with BRAF
    Ohnishi K; Nakayama K; Ishikawa M; Ishibashi T; Yamashita H; Nakamura K; Minamoto T; Iida K; Razia S; Ishikawa N; Kyo S
    Arch Gynecol Obstet; 2020 Aug; 302(2):487-495. PubMed ID: 32556513
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HER2/ ERBB2 Immunohistochemical Expression and Copy Number Status in Ovarian Mucinous Tumors.
    Smithgall MC; Yemelyanova A; Mathew S; Gogineni S; He B; Zhang T; Robinson BD; Tu JJ
    Int J Gynecol Pathol; 2024 Mar; 43(2):134-139. PubMed ID: 37406458
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serous and mucinous borderline ovarian tumours: differences in clinical presentation, high-risk histopathological features, and lethal recurrence rates.
    Vasconcelos I; Darb-Esfahani S; Sehouli J
    BJOG; 2016 Mar; 123(4):498-508. PubMed ID: 26705090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Staging with Unilateral Salpingo-Oophorectomy and Expert Pathological Review Result in No Recurrences in a Series of 81 Intestinal-Type Mucinous Borderline Ovarian Tumors.
    Dewilde K; Moerman P; Leunen K; Amant F; Neven P; Vergote I
    Gynecol Obstet Invest; 2018; 83(1):65-69. PubMed ID: 28689208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular characterization of 103 ovarian serous and mucinous tumors.
    Vereczkey I; Serester O; Dobos J; Gallai M; Szakács O; Szentirmay Z; Tóth E
    Pathol Oncol Res; 2011 Sep; 17(3):551-9. PubMed ID: 21136228
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mucinous tumors of the ovary: a clinicopathologic study of 196 borderline tumors (of intestinal type) and carcinomas, including an evaluation of 11 cases with 'pseudomyxoma peritonei'.
    Lee KR; Scully RE
    Am J Surg Pathol; 2000 Nov; 24(11):1447-64. PubMed ID: 11075847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes.
    Meagher NS; Gorringe KL; Wakefield M; Bolithon A; Pang CNI; Chiu DS; Anglesio MS; Mallitt KA; Doherty JA; Harris HR; Schildkraut JM; Berchuck A; Cushing-Haugen KL; Chezar K; Chou A; Tan A; Alsop J; Barlow E; Beckmann MW; Boros J; Bowtell DDL; ; Brand AH; Brenton JD; Campbell I; Cheasley D; Cohen J; Cybulski C; Elishaev E; Erber R; Farrell R; Fischer A; Fu Z; Gilks B; Gill AJ; ; Gourley C; Grube M; Harnett PR; Hartmann A; Hettiaratchi A; Høgdall CK; Huzarski T; Jakubowska A; Jimenez-Linan M; Kennedy CJ; Kim BG; Kim JW; Kim JH; Klett K; Koziak JM; Lai T; Laslavic A; Lester J; Leung Y; Li N; Liauw W; Lim BWX; Linder A; Lubiński J; Mahale S; Mateoiu C; McInerny S; Menkiszak J; Minoo P; Mittelstadt S; Morris D; Orsulic S; Park SY; Pearce CL; Pearson JV; Pike MC; Quinn CM; Mohan GR; Rao J; Riggan MJ; Ruebner M; Salfinger S; Scott CL; Shah M; Steed H; Stewart CJR; Subramanian D; Sung S; Tang K; Timpson P; Ward RL; Wiedenhoefer R; Thorne H; ; Cohen PA; Crowe P; Fasching PA; Gronwald J; Hawkins NJ; Høgdall E; Huntsman DG; James PA; Karlan BY; Kelemen LE; Kommoss S; Konecny GE; Modugno F; Park SK; Staebler A; Sundfeldt K; Wu AH; Talhouk A; Pharoah PDP; Anderson L; DeFazio A; Köbel M; Friedlander ML; Ramus SJ
    Clin Cancer Res; 2022 Dec; 28(24):5383-5395. PubMed ID: 36222710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comprehensive immunohistochemical analysis of IMP2 and IMP3 in 542 cases of ovarian tumors.
    Němejcová K; Bártů MK; Michálková R; Drozenová J; Fabian P; Fadare O; Hausnerová J; Laco J; Matěj R; Méhes G; Singh N; Stolnicu S; Škapa P; Švajdler M; Stružinská I; Cibula D; Kocian R; Lax SF; McCluggage WG; Dundr P
    Diagn Pathol; 2023 Feb; 18(1):15. PubMed ID: 36740684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retrospective study of characteristics and hyperthermia intraperitoneal perfusion in mucinous borderline ovarian tumor and mucinous ovarian carcinoma.
    He X; Ying R; Jia L; Li Y; Li R
    Gland Surg; 2023 Apr; 12(4):453-464. PubMed ID: 37200926
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinicopathologic Features and Risk Factors for Recurrence of Mucinous Borderline Ovarian Tumors: A Retrospective Study With Follow-up of More Than 10 Years.
    Sun L; Li N; Song Y; Wang G; Zhao Z; Wu L
    Int J Gynecol Cancer; 2018 Nov; 28(9):1643-1649. PubMed ID: 30365456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mucinous tumors of the ovary: a clinicopathologic analysis of 75 borderline tumors (of intestinal type) and carcinomas.
    Rodríguez IM; Prat J
    Am J Surg Pathol; 2002 Feb; 26(2):139-52. PubMed ID: 11812936
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progression of Cystadenoma to Mucinous Borderline Ovarian Tumor in Young Females: Case Series and Literature Review.
    Beroukhim G; Ozgediz D; Cohen PJ; Hui P; Morotti R; Schwartz PE; Yang-Hartwich ; Vash-Margita A
    J Pediatr Adolesc Gynecol; 2022 Jun; 35(3):359-367. PubMed ID: 34843973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.